The U.S. Food and Drug Administration announced a joint meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee Meeting to discuss Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Read more at http://www.fda.gov/AdvisoryCommittees/Calendar/ucm214816.htm.
FDA announces July 22-23 meeting to discuss extended-release and long-acting opioid analgesics
Most Recent Content
For Nurse Practitioners
Menopause and Sleep Problems
Data shows that sleep disturbances increase in prevalence during the menopausal transition, with the most common complaint being nighttime awakenings.
Take our quick three-question survey...
